Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
OKYO Pharma Limited Sponsored ADR ( (OKYO) ) just unveiled an announcement.
On March 19, 2026, OKYO Pharma announced that Panetta Partners Limited, an entity in which Executive Chairman and founder Gabriele Cerrone has a beneficial interest, acquired 10,119 of the company’s ordinary shares on Nasdaq at $1.59, increasing his total holding to 10,526,416 shares. The move follows OKYO’s completion of a successful Phase 2 trial of urcosimod in neuropathic corneal pain and comes as the company prepares to start a roughly 150-patient Phase 2b/3 multiple-dose study this year, underscoring management’s confidence in its lead asset and strategic focus in ocular pain and inflammation.
The most recent analyst rating on (OKYO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Neutral.
The score is primarily held down by weak financial fundamentals (pre-revenue, ongoing losses, negative free cash flow, and negative equity) and bearish technicals (below key moving averages with negative MACD). Improved 2025 cost control and a debt-free balance sheet provide only limited offset.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited is a clinical-stage biopharmaceutical company listed on the Nasdaq Capital Market, focused on developing innovative therapies for neuropathic corneal pain and inflammatory eye diseases. Its lead candidate, urcosimod, a ChemR23 agonist peptide, has shown anti-inflammatory and pain-reducing activity in preclinical models and has delivered positive results in Phase 2 trials for dry eye disease and neuropathic corneal pain.
Average Trading Volume: 271,117
Technical Sentiment Signal: Strong Sell
Current Market Cap: $83.22M
Learn more about OKYO stock on TipRanks’ Stock Analysis page.